SPRB News

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences to Participate in the Oppenheimer 36 th Annual Healthcare Life Sciences Conference

Spruce Biosciences to Participate in the Oppenheimer 36 th Annual Healthcare Life Sciences Conference

Long-Term Data Presented at the 22 nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates